{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T22:20:09Z","timestamp":1785018009640,"version":"3.55.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T00:00:00Z","timestamp":1713139200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012175","name":"Zhejiang Traditional Chinese Medicine Administration","doi-asserted-by":"publisher","award":["2022ZQ013"],"award-info":[{"award-number":["2022ZQ013"]}],"id":[{"id":"10.13039\/501100012175","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81973861"],"award-info":[{"award-number":["81973861"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008867","name":"Department of Education of Zhejiang Province","doi-asserted-by":"publisher","award":["Y202249272"],"award-info":[{"award-number":["Y202249272"]}],"id":[{"id":"10.13039\/501100008867","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-breast-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.clbc.2024.04.006","type":"journal-article","created":{"date-parts":[[2024,4,14]],"date-time":"2024-04-14T02:00:55Z","timestamp":1713060055000},"page":"463-472.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Real-World Data on Pathological Response and Survival Outcomes After Neoadjuvant Chemotherapy in HER2-Low Breast Cancer Patients"],"prefix":"10.1016","volume":"24","author":[{"given":"Dandan","family":"Guan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyang","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajuan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaopeng","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuli","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clbc.2024.04.006_bib0001","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clbc.2024.04.006_bib0002","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S0140-6736(16)32616-2","article-title":"11 years\u2019 follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial","volume":"389","author":"Cameron","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.clbc.2024.04.006_bib0003","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1703643","article-title":"Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer","volume":"377","author":"von Minckwitz","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2024.04.006_bib0004","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/s41571-019-0299-9","article-title":"Towards personalized treatment for early stage HER2-positivenbreast cancer","volume":"17","author":"Goutsouliak","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.clbc.2024.04.006_bib0005","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1200\/JCO.19.01455","article-title":"NSABP B-47\/NRG oncology phase III randomized trial comparing adjuvant chemotherapy with or without trastuzumab in high-risk invasive breast cancer negative for HER2 by FISH and with IHC 1+ or 2","volume":"38","author":"Fehrenbacher","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2024.04.006_bib0006","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S1470-2045(19)30328-6","article-title":"Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study","volume":"20","author":"Banerji","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2024.04.006_bib0007","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1248\/cpb.c18-00744","article-title":"The latest research and development into the antibody-drug conjugate, (Fam-) trastuzumab deruxtecan (DS-8201a), for HER2 cancer therapy","volume":"67","author":"Nakada","year":"2019","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"10.1016\/j.clbc.2024.04.006_bib0008","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1200\/JCO.19.02318","article-title":"Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: results from a phase Ib study","volume":"38","author":"Modi","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2024.04.006_bib0009","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1470-2045(19)30097-X","article-title":"Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study","volume":"20","author":"Tamura","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2024.04.006_bib0010","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1200\/JCO.19.02488","article-title":"HER2-low breast cancer: pathological and clinical landscape","volume":"38","author":"Tarantino","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2024.04.006_bib0011","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1200\/EDBK_201313","article-title":"New and important changes in the TNM staging system for breast cancer","volume":"38","author":"Hortobagyi","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"1","key":"10.1016\/j.clbc.2024.04.006_bib0012","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3816\/CBC.2004.n.011","article-title":"HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues","volume":"5","author":"Owens","year":"2004","journal-title":"Clin Breast Cancer"},{"issue":"1","key":"10.1016\/j.clbc.2024.04.006_bib0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41523-020-00208-2","article-title":"Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer","volume":"7","author":"Schettini","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.clbc.2024.04.006_bib0014","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1200\/JCO.2009.25.6529","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer","volume":"28","author":"Hammond","year":"2010","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.clbc.2024.04.006_bib0015","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1245\/s10434-018-6486-6","article-title":"Eighth edition of the AJCC cancer staging manual: breast cancer","volume":"25","author":"Giuliano","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clbc.2024.04.006_bib0016","article-title":"Pathological complete response in neoadjuvant treatment of high-risk early-stage breast cancer: use as an endpoint to support accelerated approval; guidance for industry; availability","author":"US Food and Drug","year":"2014","journal-title":"Federal Register"},{"issue":"5","key":"10.1016\/j.clbc.2024.04.006_bib0017","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.3390\/cancers13051015","article-title":"The exciting new field of HER2-low breast cancer treatment","volume":"13","author":"Eiger","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.clbc.2024.04.006_bib0018","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s10549-018-5020-7","article-title":"PAM50 for prediction of response to neoadjuvant chemotherapy for ER-positive breast cancer","volume":"173","author":"Ohara","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"10.1016\/j.clbc.2024.04.006_bib0019","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1093\/annonc\/mdx397","article-title":"Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer","volume":"28","author":"Fujii","year":"2017","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.clbc.2024.04.006_bib0020","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/ajcp\/aqy028","article-title":"Low estrogen receptor (ER)-positive breast cancer and neoadjuvantsystemic chemotherapy: is response similar to typical ER-positive or ER-negative disease?","volume":"150","author":"Landmann","year":"2018","journal-title":"Am J Clin Pathol"},{"issue":"1","key":"10.1016\/j.clbc.2024.04.006_bib0021","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41523-021-00308-7","article-title":"Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant\/adjuvant chemotherapy","volume":"7","author":"Dieci","year":"2021","journal-title":"NPJ Breast Cancer"},{"issue":"4S","key":"10.1016\/j.clbc.2024.04.006_bib0022","article-title":"Abstract PS4-22: prevalence of HER2-low and HER2-zero subgroups and correlation with response to neoadjuvant chemotherapy (NACT) in patients with HER2-negative breast cancer","volume":"81","author":"Reinert","year":"2021","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.clbc.2024.04.006_bib0023","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s10549-021-06365-7","article-title":"HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer","volume":"190","author":"de Moura Leite","year":"2021","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"10.1016\/j.clbc.2024.04.006_bib0024","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S1470-2045(21)00301-6","article-title":"Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials","volume":"22","author":"Denkert","year":"2021","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.clbc.2024.04.006_bib0025","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s12282-021-01303-3","article-title":"The frequency of low HER2 expression in breast cancer and a comparison of prognosis between patients with HER2-low and HER2-negative breast cancer by HR status","volume":"29","author":"Horisawa","year":"2022","journal-title":"Breast Cancer"},{"key":"10.1016\/j.clbc.2024.04.006_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102538","article-title":"Comparison of HER2-zero and HER2-low in terms of clinicopathological factors and survival in early-stage breast cancer: A systematic review and meta-analysis","volume":"115","author":"Ergun","year":"2023","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"10.1016\/j.clbc.2024.04.006_bib0027","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1158\/2159-8290.CD-ND2022-0020","article-title":"T-DXd keeps shining in breast cancer","volume":"13","year":"2023","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clbc.2024.04.006_bib0028","unstructured":"2022 SABCS-GS2-03. Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone receptor positive breast cancer (a phase II, multicenter, open-label trial to evaluate the safety and efficacy of trastuzumab deruxtecan (T-DXDa) with or without anastrozole for HER2 low hormone receptor positive (HR+) breast cancer in the neoadjuvant setting)."},{"key":"10.1016\/j.clbc.2024.04.006_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102222","article-title":"Neoadjuvant approach as a platform for treatment personalization: focus on HER2-positive and triple-negative breast cancer","volume":"98","author":"Miglietta","year":"2021","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"10.1016\/j.clbc.2024.04.006_bib0030","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1002\/cncr.35101","article-title":"HER2-low heterogeneity between primary and paired recurrent\/metastatic breast cancer: Implications in treatment and prognosis","volume":"130","author":"Lin","year":"2024","journal-title":"Cancer."}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152682092400106X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152682092400106X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T14:53:58Z","timestamp":1718895238000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152682092400106X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S152682092400106X"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2024.04.006","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Data on Pathological Response and Survival Outcomes After Neoadjuvant Chemotherapy in HER2-Low Breast Cancer Patients","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2024.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}